ovarian cancer diagnostics and treatments are in vogue with the market .. DNDN, PRR and now HTX. and for the CEO to call the biomarker a major coup is promising. btw, HTX too has been in talks with various players for marketing and distribution.. and the acceptance of its paper will open up markets for it. ofcourse, winning the award should make the asian market a sure shot.
